Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 03:00PM GMT
Release Date Price: $135 (-3.16%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst

Hi, everyone. My name is Maurice Raycroft and I'm one of the biotech analysts at Jefferies. I would like to introduce Yvonne Greenstreet, the CEO of Alnylam. Great to see you, Yvonne, and thanks so much for joining us today.

Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - CEO & Director

Thanks, Maurice. And a pleasure to be here and to be in person again across the live audience. It's a lot more fun doing it with you today. So I'm just going to make a few introductory remarks if that's the case but I just want to remind people that Alnylam is the leading RNAi company. We're incredibly proud of our progress. We now have 4 marketed medicines, 3 that we are commercializing ourselves ONPATTRO, GIVLAARI and OXLUMO and Leqvio which has been commercialized by Novartis. We have a very rich clinical pipeline, which continues to deliver exciting progress. And you may have seen today that we are sharing the results from a Phase II study with Cemdisiran in patients with IgA nephropathy.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot